Top

Published in:

Open Access 01-12-2013 | Review

Creation of a cardiotropic adeno-associated virus: the story of viral directed evolution

Authors: Lin Yang, Xiao Xiao

Published in: Virology Journal | Issue 1/2013

Abstract

Adeno-associated virus (AAV) is an important vector system for human gene therapy. Although use of AAV serotypes can result in efficient myocardial gene transfer, improvements in the transduction efficiency and specificity are still required. As a method for artificial modification and selection of gene function, directed evolution has been used for diverse applications in genetic engineering of enzymes and proteins. Since 2000, pioneering work has been performed on directed evolution of viral vectors. We further attempted to evolve the AAV using DNA shuffling and in vivo biopanning in a mouse model. An AAVM41 mutant was characterized, which was found to have improved transduction efficiency and specificity in myocardium, an attribute unknown for any natural AAV serotypes. This review focuses on the development of AAV vector for cardiac gene transfer, the history of directed evolution of viral vectors, and our creation of a cardiotropic AAV, which might have implications for the future design and application of viral vectors.

Available only for authorised users

Sonntag F, Schmidt K, Kleinschmidt JA: A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci USA 2010, 107: 10220-10225. 10.1073/pnas.1001673107PubMedPubMedCentralCrossRef

Ding W, Zhang L, Yan Z, Engelhardt JF: Intracellular trafficking of adeno-associated viral vectors. Gene Ther 2005, 12: 873-880. 10.1038/sj.gt.3302527PubMedCrossRef

Nonnenmacher M, Weber T: Intracellular transport of recombinant adeno-associated virus vectors. Gene Ther 2012, 19: 649-658. 10.1038/gt.2012.6PubMedPubMedCentralCrossRef

Schnepp BC, Clark KR, Klemanski DL, Pacak CA, Johnson PR: Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol 2003, 77: 3495-3504. 10.1128/JVI.77.6.3495-3504.2003PubMedPubMedCentralCrossRef

Zhu J, Huang X, Yang Y: The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest 2009, 119: 2388-2398. 10.1172/JCI37607PubMedPubMedCentralCrossRef

Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell’Osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J: Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med 2008, 358: 2240-2248. 10.1056/NEJMoa0802315PubMedPubMedCentralCrossRef

Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR: Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med 2008, 358: 2231-2239. 10.1056/NEJMoa0802268PubMedCrossRef

Cideciyan AV, Aleman TS, Boye SL, Schwartz SB, Kaushal S, Roman AJ, Pang JJ, Sumaroka A, Windsor EA, Wilson JM, Flotte TR, Fishman GA, Heon E, Stone EM, Byrne BJ, Jacobson SG, Hauswirth WW: Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA 2008, 105: 15112-15117. 10.1073/pnas.0807027105PubMedPubMedCentralCrossRef

Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ: Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet 2007, 369: 2097-2105. 10.1016/S0140-6736(07)60982-9PubMedCrossRef

10.

Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ, Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators: Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 2011, 124: 304-313. 10.1161/CIRCULATIONAHA.111.022889PubMedCrossRef

11.

Mendell JR, Rodino-Klapac LR, Rosales XQ, Coley BD, Galloway G, Lewis S, Malik V, Shilling C, Byrne BJ, Conlon T, Campbell KJ, Bremer WG, Taylor LE, Flanigan KM, Gastier-Foster JM, Astbury C, Kota J, Sahenk Z, Walker CM, Clark KR: Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 2010, 68: 629-638. 10.1002/ana.22251PubMedPubMedCentralCrossRef

12.

Mingozzi F, High KA: Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011, 12: 341-355.PubMedCrossRef

13.

Samulski RJ, Berns KI, Tan M, Muzyczka N: Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci USA 1982, 79: 2077-2081. 10.1073/pnas.79.6.2077PubMedPubMedCentralCrossRef

14.

Xiao X, Li J, Samulski RJ: Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996, 70: 8098-8108.PubMedPubMedCentral

15.

Fisher KJ, Jooss K, Alston J, Yang Y, Haecker SE, High K, Pathak R, Raper SE, Wilson JM: Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 1997, 3: 306-312. 10.1038/nm0397-306PubMedCrossRef

16.

Svensson EC, Marshall DJ, Woodard K, Lin H, Jiang F, Chu L, Leiden JM: Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors. Circulation 1999, 99: 201-205. 10.1161/01.CIR.99.2.201PubMedCrossRef

17.

Melo LG, Agrawal R, Zhang L, Rezvani M, Mangi AA, Ehsan A, Griese DP, Dell’Acqua G, Mann MJ, Oyama J, Yet SF, Layne MD, Perrella MA, Dzau VJ: Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation 2002, 105: 602-607. 10.1161/hc0502.103363PubMedCrossRef

18.

Iwanaga Y, Hoshijima M, Gu Y, Iwatate M, Dieterle T, Ikeda Y, Date MO, Chrast J, Matsuzaki M, Peterson KL, Chien KR, Ross J Jr: Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest 2004, 113: 727-736.PubMedPubMedCentralCrossRef

19.

Hoshijima M, Ikeda Y, Iwanaga Y, Minamisawa S, Date MO, Gu Y, Iwatate M, Li M, Wang L, Wilson JM, Wang Y, Ross J Jr, Chien KR: Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 2002, 8: 864-871.PubMed

20.

Yue Y, Li Z, Harper SQ, Davisson RL, Chamberlain JS, Duan D: Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation 2003, 108: 1626-1632. 10.1161/01.CIR.0000089371.11664.27PubMedPubMedCentralCrossRef

21.

Gao G, Vandenberghe LH, Wilson JM: New recombinant serotypes of AAV vectors. Curr Gene Ther 2005, 5: 285-297. 10.2174/1566523054065057PubMedCrossRef

22.

Su H, Huang Y, Takagawa J, Barcena A, Arakawa-Hoyt J, Ye J, Grossman W, Kan YW: AAV serotype-1 mediates early onset of gene expression in mouse hearts and results in better therapeutic effect. Gene Ther 2006, 13: 1495-1502. 10.1038/sj.gt.3302787PubMedCrossRef

23.

Palomeque J, Chemaly ER, Colosi P, Wellman JA, Zhou S, Del Monte F, Hajjar RJ: Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo. Gene Ther 2007, 14: 989-997. 10.1038/sj.gt.3302895PubMedCrossRef

24.

Rengo G, Lymperopoulos A, Zincarelli C, Donniacuo M, Soltys S, Rabinowitz JE, Koch WJ: Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 2009, 119: 89-98. 10.1161/CIRCULATIONAHA.108.803999PubMedPubMedCentralCrossRef

25.

Gregorevic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L, Miller DG, Russell DW, Chamberlain JS: Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 2004, 10: 828-834. 10.1038/nm1085PubMedPubMedCentralCrossRef

26.

Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J, Chen C, Li J, Xiao X: Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 2005, 23: 321-328. 10.1038/nbt1073PubMedCrossRef

27.

Zhu T, Zhou L, Mori S, Wang Z, McTiernan CF, Qiao C, Chen C, Wang DW, Li J, Xiao X: Sustained whole-body functional rescue in congestive heart failure and muscular dystrophy hamsters by systemic gene transfer. Circulation 2005, 112: 2650-2659. 10.1161/CIRCULATIONAHA.105.565598PubMedCrossRef

28.

Inagaki K, Fuess S, Storm TA, Gibson GA, Mctiernan CF, Kay MA, Nakai H: Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 2006, 14: 45-53. 10.1016/j.ymthe.2006.03.014PubMedPubMedCentralCrossRef

29.

Pacak CA, Mah CS, Thattaliyath BD, Conlon TJ, Lewis MA, Cloutier DE, Zolotukhin I, Tarantal AF, Byrne BJ: Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 2006, 99: e3-e9. 10.1161/01.RES.0000237661.18885.f6PubMedCrossRef

30.

Townsend D, Blankinship MJ, Allen JM, Gregorevic P, Chamberlain JS, Metzger JM: Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol Ther 2007, 15: 1086-1092.PubMed

31.

Shin JH, Bostick B, Yue Y, Hajjar R, Duan D: SERCA2a gene transfer improves electrocardiographic performance in aged mdx mice. J Transl Med 2011, 9: 132. 10.1186/1479-5876-9-132PubMedPubMedCentralCrossRef

32.

Pleger ST, Shan C, Ksienzyk J, Bekeredjian R, Boekstegers P, Hinkel R, Schinkel S, Leuchs B, Ludwig J, Qiu G, Weber C, Raake P, Koch WJ, Katus HA, Müller OJ, Most P: Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med 2011, 3: 92ra64. 10.1126/scitranslmed.3002097PubMedPubMedCentralCrossRef

33.

Müller OJ, Leuchs B, Pleger ST, Grimm D, Franz WM, Katus HA, Kleinschmidt JA: Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res 2006, 70: 70-78. 10.1016/j.cardiores.2005.12.017PubMedCrossRef

34.

Asokan A, Conway JC, Phillips JL, Li C, Hegge J, Sinnott R, Yadav S, DiPrimio N, Nam HJ, Agbandje-McKenna M, McPhee S, Wolff J, Samulski RJ: Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol 2010, 28: 79-82. 10.1038/nbt.1599PubMedPubMedCentralCrossRef

35.

Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM: Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002, 99: 11854-11859. 10.1073/pnas.182412299PubMedPubMedCentralCrossRef

36.

Gao G, Alvira MR, Somanathan S, Lu Y, Vandenberghe LH, Rux JJ, Calcedo R, Sanmiguel J, Abbas Z, Wilson JM: Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci USA 2003, 100: 6081-6086. 10.1073/pnas.0937739100PubMedPubMedCentralCrossRef

37.

Soong NW, Nomura L, Pekrun K, Reed M, Sheppard L, Dawes G, Stemmer WP: Molecular breeding of viruses. Nat Genet 2000, 25: 436-439. 10.1038/78132PubMedCrossRef

38.

Stemmer WP: DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution. Proc Natl Acad Sci USA 1994, 91: 10747-10751. 10.1073/pnas.91.22.10747PubMedPubMedCentralCrossRef

39.

Müller OJ, Kaul F, Weitzman MD, Pasqualini R, Arap W, Kleinschmidt JA, Trepel M: Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 2003, 21: 1040-1046. 10.1038/nbt856PubMedCrossRef

40.

Maheshri N, Koerber JT, Kaspar BK, Schaffer DV: Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 2006, 24: 198-204. 10.1038/nbt1182PubMedCrossRef

41.

Yang L, Jiang J, Drouin LM, Agbandje-McKenna M, Chen C, Qiao C, Pu D, Hu X, Wang DZ, Li J, Xiao X: A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci USA 2009, 106: 3946-3951. 10.1073/pnas.0813207106PubMedPubMedCentralCrossRef

42.

Xiao PJ, Li C, Neumann A, Samulski RJ: Quantitative 3D tracing of gene-delivery viral vectors in human cells and animal tissues. Mol Ther 2012, 20: 317-328. 10.1038/mt.2011.250PubMedPubMedCentralCrossRef

43.

Koerber JT, Klimczak R, Jang JH, Dalkara D, Flannery JG, Schaffer DV: Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol Ther 2009, 17: 2088-2095. 10.1038/mt.2009.184PubMedPubMedCentralCrossRef

44.

Jang JH, Koerber JT, Kim JS, Asuri P, Vazin T, Bartel M, Keung A, Kwon I, Park KI, Schaffer DV: An evolved adeno-associated viral variant enhances gene delivery and gene targeting in neural stem cells. Mol Ther 2011, 19: 667-675. 10.1038/mt.2010.287PubMedPubMedCentralCrossRef

45.

Excoffon KJ, Koerber JT, Dickey DD, Murtha M, Keshavjee S, Kaspar BK, Zabner J, Schaffer DV: Directed evolution of adeno-associated virus to an infectious respiratory virus. Proc Natl Acad Sci USA 2009, 106: 3865-3870. 10.1073/pnas.0813365106PubMedPubMedCentralCrossRef

46.

Michelfelder S, Kohlschütter J, Skorupa A, Pfennings S, Müller O, Kleinschmidt JA, Trepel M: Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries. PLoS One 2009, 4: e5122. 10.1371/journal.pone.0005122PubMedPubMedCentralCrossRef

47.

Ying Y, Müller OJ, Goehringer C, Leuchs B, Trepel M, Katus HA, Kleinschmidt JA: Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library. Gene Ther 2010, 17: 980-990. 10.1038/gt.2010.44PubMedCrossRef

48.

Pulicherla N, Shen S, Yadav S, Debbink K, Govindasamy L, Agbandje-McKenna M, Asokan A: Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol Ther 2011, 19: 1070-1078. 10.1038/mt.2011.22PubMedPubMedCentralCrossRef

49.

Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, Dake M, Kaye R, Razavi M, Zajko A, Zehnder J, Rustagi PK, Nakai H, Chew A, Leonard D, Wright JF, Lessard RR, Sommer JM, Tigges M, Sabatino D, Luk A, Jiang H, Mingozzi F, Couto L, Ertl HC, High KA, Kay MA: Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006, 12: 342-347. 10.1038/nm1358PubMedCrossRef

Title: Creation of a cardiotropic adeno-associated virus: the story of viral directed evolution
Authors: Lin Yang
Xiao Xiao
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Virology Journal / Issue 1/2013
Electronic ISSN: 1743-422X
DOI: https://doi.org/10.1186/1743-422X-10-50

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Key elements of the human bocavirus type 1 (HBoV1) promoter and its trans-activation by NS1 protein

Viruses and neurodegeneration

Cellular phosphoinositides and the maturation of bluetongue virus, a non-enveloped capsid virus

Use of immuno-dominant epitope derived from genotype 4 as a diagnostic reagent for detecting the antibodies against Hepatitis E Virus

Effects of southern rice black-streaked dwarf virus on the development and fecundity of its vector, Sogatella furcifera

Histopathological changes in the liver of tree shrew (Tupaia belangeri chinensis) persistently infected with hepatitis B virus

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials